Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651220 · ClinicalTrials.gov registry record · Phase 3
Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris
A Phase 3 study of Acne, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,001
- Enrollment target
- 20
- Study locations
NCT02651220: Completed Phase 3 study of Acne, sponsored by Actavis.
NCT02651220 is a Phase 3 study of Acne that has completed, run by Actavis. The registered enrollment target is 1,001 participants, above the 104-participant average among 26 other Acne trials with a reported enrollment target (863% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02651220, a Phase 3 study of Acne, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,001 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris
Conditions Studied
Interventions
- DRUG placebo gel
- DRUG Epiduo® Forte Gel
- DRUG Adapalene and Benzoyl Peroxide Gel
Study Locations (20)
California
- Site 112 - Anaheim
- Site 110 - Long Beach
- Site 111 - Los Angeles
- Site 104 - San Diego
- Site 113 - West Covina
Florida
- Site 101 - Brandon
- Site 119 - Jacksonville
- Site 114 - Miami
- Site 115 - Miami
- Site 116 - Miramar
Arizona
- Site 103 - Mesa
- Site 109 - Tucson
Indiana
- Site 105 - Carmel
- Site 120 - New Albany
Other
- Site 117 - Belize City
- Site 118 - Belize City
Illinois
- Site 102 - Arlington Heights
Nevada
- Site 107 - Henderson
North Carolina
- Site 106 - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,001 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
What the finished NCT02651220 record still lists
NCT02651220 is an interventional study that assigns participants to a tested intervention. Its 1,001 participants enrollment target places it among the larger protocols in the corpus, above the 104-participant average among 26 other Acne trials with a reported enrollment target (863% higher).
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 3 interventions - of which placebo gel is the first listed.
NCT02651220 names 20 study sites across 9 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02651220 about?
NCT02651220 is a clinical study titled "Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris". A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma)...
What is the current status of trial NCT02651220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,001 participants. The study started on 2015-11. Estimated completion is 2016-10.
What conditions does trial NCT02651220 study?
This clinical trial studies the following conditions: Acne.
What interventions are being tested in trial NCT02651220?
The interventions under investigation include: placebo gel (DRUG), Epiduo® Forte Gel (DRUG), Adapalene and Benzoyl Peroxide Gel (DRUG).
Who is sponsoring clinical trial NCT02651220?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02651220 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02651220's enrollment target sits among peer trials
1,001 1st of 26 higher than 26 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
RECRUITING · Phase 1
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
RECRUITING · Phase 1
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
RECRUITING · Phase 1
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia